These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19516276)

  • 1. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
    Gutman D; Morales AA; Boise LH
    Leukemia; 2009 Nov; 23(11):2181-3. PubMed ID: 19516276
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
    Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
    Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
    Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
    Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
    Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib for the treatment of multiple myeloma.
    Lue J; Goel S; Mazumder A
    Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
    Rukavitsyn OA
    Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936
    [No Abstract]   [Full Text] [Related]  

  • 10. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors as therapeutics.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
    Buzzeo R; Enkemann S; Nimmanapalli R; Alsina M; Lichtenheld MG; Dalton WS; Beaupre DM
    Clin Cancer Res; 2005 Aug; 11(16):6057-64. PubMed ID: 16115951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
    Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
    Catley L; Weisberg E; Kiziltepe T; Tai YT; Hideshima T; Neri P; Tassone P; Atadja P; Chauhan D; Munshi NC; Anderson KC
    Blood; 2006 Nov; 108(10):3441-9. PubMed ID: 16728695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
    Kuhn DJ; Hunsucker SA; Chen Q; Voorhees PM; Orlowski M; Orlowski RZ
    Blood; 2009 May; 113(19):4667-76. PubMed ID: 19050304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
    Landowski TH; Megli CJ; Nullmeyer KD; Lynch RM; Dorr RT
    Cancer Res; 2005 May; 65(9):3828-36. PubMed ID: 15867381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.
    Goranov SE; Goranova-Marinova VS
    Folia Med (Plovdiv); 2005; 47(3-4):11-9. PubMed ID: 16761388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
    Stessman HA; Lulla A; Xia T; Mitra A; Harding T; Mansoor A; Myers CL; Van Ness BG; Dolloff NG
    Leukemia; 2014 Nov; 28(11):2263-7. PubMed ID: 25005244
    [No Abstract]   [Full Text] [Related]  

  • 20. [Proteasome inhibitors].
    Hatake K; Mishima Y; Terui Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.